Parallel Advisors
KNTE

Parallel Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Parallel Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed – – 3560
2022
Q3 		$0 Buy
+10
New +$131 ﹤0.01% 3588
2021
Q4 		– Sell
-199
Closed -$5K – 3356
2021
Q3 		$5K Buy
+199
New +$4.33K ﹤0.01% 2402

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Parallel Advisors's KNTE Position: Q4 2022 in Review

Parallel Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 10 shares.

Parallel Advisors first reported a position in KNTE in Q3 2021 and held it in 2 quarters. The position peaked at $5K in Q3 2021. 78 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Parallel Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 10 Kinnate Biopharma Inc. Common Stock shares in Q4 2022.
  • Parallel Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Parallel Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $5K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.